451 patents
Page 2 of 23
Utility
Combination therapy with notch and PD-1 or PD-L1 inhibitors
28 Nov 23
The present invention provides medicaments for use in treating and methods of treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, Sung cancer, non small-cell lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral squamous cell carcinoma, skin cancer, medul!ob!astoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, desmoid tumor, soft tissue sarcoma, or adenoid cystic carcinoma in a patient comprising combination therapy with 4,4,4-tri-fluoro-N-[(1S)-2˜[[(7S)-5-(2-hydroxyemyl)-6-oxo-7H-pyrido[23-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyljbutanamide, or a pharmaceutically acceptable salt or hydrate thereof, and a PD-1 or a PD-L1 inhibitor selected from pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab.
Mark Harrath Bender, Hong Gao, Bharvin Kumar Patel
Filed: 8 May 20
Utility
Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
28 Nov 23
The embodiments of present invention provide processes and an intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate, and formulations and product forms, such as tablets, made by these processes.
Aktham Aburub, David Andrew Coates, Scott Alan Frank, Mark Steven Kerr, Roger Ryan Rothhaar, Radhe Krishan Vaid
Filed: 14 Apr 23
Utility
Secured Medication Transfer System
23 Nov 23
A vial adaptor and needle assembly are disclosed for use with a vial containing a medication, such as insulin.
Keith Daniel Alsberg, Christopher John DeMaria, Kenneth James Micklash, II, Gary Harlan Paulsen
Filed: 2 Aug 23
Utility
Methods for Reducing Host Cell Protein Content In Protein Purification Processes
23 Nov 23
The present disclosure relates to methods for reducing host cell protein content in a protein preparation recombinantly produced in a host cell in the manufacturing process of proteins intended for administration to a patient.
Brian David Bowes, Lara Ellen Krebs
Filed: 4 Oct 21
Utility
PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL Compounds for the Treatment of Pancreatic Cancer
23 Nov 23
The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.
Marta Maria Cifuentes-Garcia, Maria Cristina Garcia Paredes
Filed: 13 Apr 23
Utility
6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN Compounds
23 Nov 23
Ana Belén BUENO MELENDO, Jayana Pankajkumar LINESWALA, Gema RUANO PLAZA, Nuria Diaz BUEZO
Filed: 6 Oct 21
Utility
AT2R Antagonists and Uses Thereof
23 Nov 23
Thomas James BEAUCHAMP, Zhaogen CHEN, Scott Eugene CONNER, Jon Andre ERICKSON, Maria Cristina GARCIA PAREDES, Jayana Pankajkumar LINESWALA, Emanuele SHER, Bishnu THAPA, Leonard Larry WINNEROSKI, II
Filed: 11 May 23
Utility
Polymorphs of an SSAO inhibitor
21 Nov 23
Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
David Michael Remick
Filed: 24 Aug 21
Utility
Protein tyrosine-tyrosine analogs and methods of using the same
21 Nov 23
PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor.
Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
Filed: 5 Oct 21
Utility
Methods for producing fabs and IgG bispecific antibodies
21 Nov 23
Methods for producing Fabs and IgG bi-specific antibodies comprising expressing nucleic acids encoding designed residues in the CH1/CL interface are provided.
Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
Filed: 14 Dec 17
Utility
Devices and Processes for Delivery of Therapeutic Fluids
16 Nov 23
A therapeutic agent delivery system includes a therapeutic agent delivery assembly carried by a housing.
William Godwin ATTERBURY, Corrie Jo BENNISON, Yelena N. DAVIS, Jeffrey LeClair ELLIS, David Arthur HOLLEY, John Paul TALLARICO, Jessica Diane YOUNG
Filed: 1 Sep 21
Utility
Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same
14 Nov 23
The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the Vα and Vβ polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells.
John Brian Mumm, Ivan Ho Chan, Scott McCauley, Scott Ogg, Martin Oft
Filed: 10 Jan 17
Utility
Oral Drug Delivery Device with Expanding Band
9 Nov 23
The present disclosure provides a drug delivery device.
Eric Gustin HASSENPFLUG, Anthony David DUONG, Erik William EDWARDS, Brian R. FORTNER, Larry Keith HOOKS, Jr., Steven HUCKABY, Trevor Alan PETREL, Sarah Louise CLARK
Filed: 15 Sep 21
Utility
Medication Delivery Device with Sensing System
9 Nov 23
Medication delivery devices are provided having a sensor in the form of a single-pole double-throw (SPDT) switch, a conversion control module that receives signals from the SPDT switch and generates an outputs a signal, and related power control circuitry.
Andrew Eric BOWYER, Joseph Edward KATUIN
Filed: 23 Aug 21
Utility
Therapeutic Uses of Tirzepatide
9 Nov 23
The present invention relates to methods for treating, preventing or delaying disorders relating to cognition, such as cognitive decline, cognitive impairment or dementia.
Matthew Paul COGHLAN, Axel HAUPT, Masahiro MURAKAMI, Jeffrey Scott RIESMEYER
Filed: 22 Jan 21
Utility
Low Dose Regimen and Formulation of a 5-METHYL-1,2,4-OXADIAZOL-3-YL Compound
26 Oct 23
William Brian KIELBASA, Dustin James MERGOTT
Filed: 23 Jul 21
Utility
KRAS Gl2C INHIBITORS
26 Oct 23
Serge Louis BOULET, Kevin Charles FORTNER, Deqi GUO, David Michael HYMAN, Sheng-Bin PENG, Chong SI
Filed: 28 Jun 23
Utility
Oscillating Fluidized Bed Oligonucleotide Synthesizer
26 Oct 23
A method and device for building an oligonucleotide on a solid phase resin within a filter reactor, wherein the method and device as used as a solid phase synthesis system.
Martin D. JOHNSON, Luke P. WEBSTER, Jessica Ann ZELINSKI, Wei-Ming SUN, Timothy Michael BRADEN, Yufei WEI
Filed: 15 May 23
Utility
Mapt Rna Interference Agents
26 Oct 23
Provided herein are MAPT RNAi agents and compositions comprising a MAPT RNAi agent.
Barbara Calamini, Sarah Katharina Fritschi, Rebecca Ruth Miles, Andrew Peter McCarthy, Douglas Raymond Perkins, Keith Geoffrey Phillips, Kaushambi Roy, Isabel Cristina Gonzalez Valcarcel, Jibo Wang, Shih-Ying Wu, Jeremy S. York
Filed: 3 May 23
Design
Button
24 Oct 23
Delroy George Dennisur, Hemant Thakorbhai Patel, Amin Sedighiamiri, Parker Eugene Trow, Hsuan Tsun Wang
Filed: 11 Apr 22